TMEM16A was recently identified as a calcium-activated chloride conductance and a key orchestrator of anion secretion in the human airway epithelium (Caputo et al 2008; Schroeder et al 2008; Yang et al 2008). It is now clinically established that promoting anion secretion in the airway leads to enhanced mucus clearance and reduced exacerbation frequency in CF patients and as such TMEM16A represents an important target for the next generation of mucokinetics. Importantly, positive regulators of TMEM16A function will be expected to be of benefit in all CF patients, irrespective of their CFTR mutational status.
https://enterprisetherapeutics.com/wp-content/uploads/2018/05/Enterprise-Therapeutics-Logo-2.png 0 0 admin https://enterprisetherapeutics.com/wp-content/uploads/2018/05/Enterprise-Therapeutics-Logo-2.png admin2016-03-02 12:26:132018-05-11 12:27:04Pharmacological characterisation of TMEM16A regulators, presented at The 13th European Cystic Fibrosis Basic Science Conference, Pisa, Italy, March 2016
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. The company is based in the UK with offices at the Sussex Innovation Centre.
Follow Us On Twitter
Twitter feed is not available at the moment.